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528A systematic review and meta-analysis of the
association between markers of hemostasis and
abdominal aortic aneurysm presence and size
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Objective: The purpose of this study was to summarize the current evidence of the association between markers of he-
mostasis and both the presence and size of abdominal aortic aneurysms (AAAs).
Methods: A systematic review and meta-analysis was performed according to Preferred Reporting Items for Systematic
reviews and Meta-Analyses guidelines by use of the search terms “aneurysm AND abdominal AND aortic AND coagu-
lation” NOT “thoracic.” Outcome data including concentration of hemostatic marker, number of patients, and signiﬁ-
cance level were recorded.
Results: A total of 22 nonrandomized studies were included in the analysis, with a total of 9862 patients. Fibrinogen mean
difference (MD) (0.43 g/L; 95% conﬁdence interval [CI], 0.28-0.58 g/L; P # .00001), D-dimer MD (325.82 ng/mL;
95% CI, 199.74-451.89 ng/mL; P # .00001), and thrombin-antithrombin III complex MD (5.58 g/L; 95% CI, 3.34-
7.83 g/L; P # .0001) were signiﬁcantly elevated in the presence of AAAs. Tissue plasminogen activator, prothrombin
fragments F1DF2, and platelet count were not shown to be signiﬁcantly different between patients with and those
without AAAs. Meta-regression of studies reporting plasma D-dimer concentration and aneurysm diameter suggests a
strong and signiﬁcant association (r2 [ 0.94; P # .0001).
Conclusions: This study suggests that the presence of AAAs is associated with increased ﬁbrin turnover, ﬁbrinolysis, and
thrombin generation, as shown by increased levels of ﬁbrinogen, D-dimer, and thrombin-antithrombin III complex. This
is clinically relevant because markers of hemostasis are independent risk factors for cardiovascular events, highlighting the
necessity of addressing all modiﬁable cardiovascular risk factors in patients with AAAs. Furthermore, the ﬁnding that
plasma D-dimer concentration appears to have a linear relationship with aneurysm diameter may be useful as a future
biomarker of AAAs. (J Vasc Surg 2014;59:528-35.)Abdominal aortic aneurysms (AAAs) are a substantial
burden on health care in most developed countries and an
important cause of years of life lost in the United Kingdom.
Efforts to reduce mortality rates from AAAs depend largely
on the early detection and elective repair of the AAA, and, in
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://dx.doi.org/10.1016/j.jvs.2013.10.088(NAAASP) is due to be fully rolled out on the basis of evi-
dence that ultrasound screening for AAAs is safe, cost-
effective, and has a high sensitivity and speciﬁcity.1 The pres-
ence of an AAA is, however, strongly associated with cardio-
vascular disease; for example, the United Kingdom Small
Aneurysm Trial observed a 28% incidence of cardiovascular
mortality over an 8-year period.2 Several studies have shown
that this risk progressively increases with aortic diameter,3
and, although much of this association is thought to be sec-
ondary to shared risk factors, several studies have shown that
circulating markers of hemostasis are elevated in patients
with aortic dilatation and that they are independently asso-
ciated with cardiovascular events.4
The nearly consistent presence of a nonocclusive mural
thrombus5 in patients with AAAs, characterized by erythro-
cyte hemagglutination and neutrophil trapping (a process
that releases free hemoglobin, leading to platelet activation,
ﬁbrin formation, and binding of plasminogen causing oxida-
tive and proteolytic injury of the arterial wall6),may drive this
coagulopathy. This activity is mainly orchestrated at the
intraluminal thrombus-blood interface,7 and thus circu-
latingmarkers of this activity could bemeasuredperipherally.
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with and those without AAAs adds to our understanding of
the pathophysiology of the disease, and several studies have
investigated their usefulness as possible biomarkers of aneu-
rysm presence and size; therefore, the purpose of this study
is to summarize the current evidence. We performed a sys-
tematic review and meta-analysis of case-control studies
comparing markers of hemostasis in patients with and those
without AAAs and of the association betweenmarkers of he-
mostasis and aneurysm diameter.
METHODS
Standard reporting guidelines set by the Preferred
Reporting Items for Systematic reviews and Meta-Analyses
(PRISMA)8 were followed to identify case-control studies
comparing plasma concentrations of markers of hemostasis
in patients with and those without AAAs and studies testing
the association between markers of hemostasis and aneu-
rysm size. Study titles and abstracts were searched through
the use of Medline and Embase databases, with the use of
Ovid Online (Version: OvidSP_UI03.04.02.112; Ovid
Technologies, Inc) on December 28, 2013, separately by
D.S. and P.S. No language restrictions or ﬁlters used to
restrict study designs were applied. Reference lists were
searched for further studies to be included.
Eligibility criteria and study selection. A compre-
hensive literature search was performed through the use
of the search terms “aneurysm AND abdominal AND
aortic AND coagulation” NOT “thoracic.” Two reviewers,
DS and PWS, individually reviewed potential studies ac-
cording to a set of eligibility criteria, with discrepancies dis-
cussed. Inclusion criteria were that the study must either
(a) be an original publication with either a case-control
design comparing markers of hemostasis in patients with
AAAs and control subjects, or (b) test the association be-
tween markers of hemostasis and aneurysm size. The
following articles were excluded: review articles, studies in
which duplicated data was published, and those pertaining
to thoracic aortic aneurysms. The quality of the non-
randomized controlled studies was evaluated by use of the
Newcastle-Ottawa Scale.9 The potential for publication
and reporting bias was assessed through the use of funnel
plots.
Data collection. Data were extracted independently
by two reviewers, DS and PWS, with any discrepancies dis-
cussed. The following outcomes were recorded: year of
publication; author; journal; concentration of marker in
AAA; concentration of marker in control; number of pa-
tients; mean; median; standard deviation (SD); interquar-
tile range (IQR); signiﬁcance level; mean aneurysm size;
and SD of aneurysm size.
Statistical analysis. The data were analyzed with the
use of Review Manager 5.2.10 Separate analyses were per-
formed for each individual outcome, with all possible papers
included in which they had published results on the
outcome under analysis. For each study, data were extracted
on mean concentrations SDs. In articles reporting the me-
dian and IQR, we took the median to be representative ofthe mean and converted the IQR into an SD.10 To assess
heterogeneity between studies, the I2 statistic was used.
Meta-analysis was performed by means of a random-
effects model in which signiﬁcant statistical heterogeneity
was identiﬁed and a ﬁxed-effects model in which it was
not identiﬁed. An a level of#.05 was used to determine sta-
tistical signiﬁcance, with outcomes reported as mean differ-
ences and conﬁdence intervals. To determine whether
biomarker concentrations were associated with AAA size,
meta-regression was performed bymeans of inverse variance
weighted linear regression. Biomarker concentrations were
compared with the reported mean/median aneurysm size
from each study. In cases in which biomarker concentrations
were reported stratiﬁed by AAA size, each size subgroup was
entered into the regression as a separate outcome. Sensitivity
analyses were performed by excluding studies with less than
100 patients and recalculating the pooled mean difference
(MD) estimates for the remaining studies.
RESULTS
Literature search. A total of 309 abstracts were iden-
tiﬁed through literature search, with three studies identiﬁed
through manual searching of reference lists from these ar-
ticles. After removal of duplicates, review of the titles and
abstracts of 254 papers was performed. A total of 27 papers
were obtained and read in full. Five studies were excluded
for the following reasons: Two studies were excluded
because they were review articles,6,11 two studies were
excluded because they compared markers of coagulation in
patients with ruptured vs nonruptured AAAs,12,13 and one
was excluded because it contained duplicate data.14
A total of 22nonrandomized studieswere included in the
analysis. Three studies15-17 reported on both a control group
of age-matched individuals and a control group with periph-
eral arterial disease. For the purpose of this analysis, the pe-
ripheral arterial disease group was excluded. Seven studies
speciﬁcally investigated the association between AAA diam-
eter and markers of hemostasis (Supplementary Table I, on-
line only).18-24 The PRISMA diagram is shown in Fig 1.
Study quality and publication bias. The Newcastle-
Ottawa scale was used to assess the quality of non-
randomized studies, with all studies scoring 7 or more of
9. Funnel plots were performed for all outcomes. All funnel
plots suggested minimal publication bias (Supplementary
Fig 1, a-f, online only).
Studies comparing patients with and those without
AAAs
Fibrinogen. A total of 12 studies16-18,20,25-31 reported
on concentrations of plasma ﬁbrinogen in patients with and
those without AAAs. The largest of these studies included
3424 patients,32 whereas the smallest contained 34 pa-
tients.29 Methods were similar between studies, with the
majority comparing AAAs diagnosed onUSS against healthy
age-matched control subjects; however, two studies used
control groups including healthy age-matched individuals
and patients with peripheral arterial disease.16,17 Ten of the
12 studies31 reported ﬁbrinogen concentrations in men and
Fig 2. Forest plot compares mean plasma concentration of ﬁbrinogen between studies. A random-effects model was
used for meta-analysis. AAA, Abdominal aortic aneurysm; CI, conﬁdence interval; SD, standard deviation.
Fig 1. Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) diagram of the review.
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rately31 and another study only reported on men.20
Nine studies revealed a signiﬁcantly higher level of
plasma ﬁbrinogen in patients with AAAs, with three
studies showing no signiﬁcant difference (Supplementary
Table I, a, online only). Pooled analysis of the data
(Fig 2) shows that patients with AAAs have a signiﬁcantly
higher plasma concentration of ﬁbrinogen (MD, 0.43 g/
L; 95% conﬁdence interval [CI], 0.28-0.58 g/L; P #
.00001). There was signiﬁcant heterogeneity between
studies (I2 ¼ 83%) and accordingly a random-effects
model was used. Sensitivity analysis was performed
and did not signiﬁcantly change the overall effect
(Supplementary Fig 2, online only). A positive associationbetween AAA size and plasma ﬁbrinogen20 has been sug-
gested; however, meta-regression of studies20,22,25,26,28
reporting AAA diameter and ﬁbrinogen concentration
did not reveal a signiﬁcant association.
Markers of ﬁbrinolysis.
D-dimer. Eleven studies reported on concentrations of
plasma D-dimer18,19,23-28,34-36 the largest of which con-
tained 126023 patients, whereas the smallest contained 28.36
Recruitment was similar between studies, all recruiting from
a hospital-based setting except for one, which also recruited
from a population setting.23 Methods varied between
studies, although in general, USS-detected AAA patients
were compared against age-matched healthy control sub-
jects. One study compared ultrasound-detected small
Fig 3. Forest plot compares mean plasma concentration of D-dimer between studies. A random-effects model was
used for meta-analysis. AAA, Abdominal aortic aneurysm; CI, conﬁdence interval; SD, standard deviation.
Fig 4. Meta-regression demonstrates the association between
abdominal aortic aneurysm (AAA) diameter and D-dimer
concentration.
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subjects28 and another compared ultrasound- or computed
tomography-detected AAA (>3 cm) patients with patients
with symptomatic atherosclerosis and age-matched control
subjects.23 Ten studies found a signiﬁcantly increased con-
centration of plasma D-dimer in patients with AAAs,
whereas one found no signiﬁcant difference (Supplementary
Table I, b, online only).
Pooled analysis of the data (Fig 3) shows patients with
AAAs have a signiﬁcantly higher plasma concentration of
D-dimer (MD, 325.82 ng/mL; 95% CI, 199.74-
451.89 ng/mL; P # .00001). There was signiﬁcant het-
erogeneity between studies (I2 ¼ 80%) and accordingly, a
random-effects model was used. Five studies reported on
the association of AAA size with plasma concentration of
D-dimer,18,19,22-24 all ﬁnding a positive association with
the largest correlation coefﬁcient value equaling 0.644.18
Meta-regression of studies reporting AAA diameter and
D-dimer concentration19,23,25,26,28,29 (Fig 4) reveals a
highly signiﬁcant, strongly positive association between
aneurysm diameter and D-dimer concentration (r2 ¼
0.94; P # .0001). Interestingly, one study23 also analyzed
the association of D-dimer with aneurysm growth rate and
found a higher concentration of D-dimer (>900 ng/mL)
in patients with a growth rate of 1.7 mm/year, whereas pa-
tients with a slower growth rate (0.7 mm/year) had a
signiﬁcantly lower D-dimer concentration (#150 ng/mL).
Two studies18,22 stood as clear outliers within the
D-dimer analysis, ﬁnding signiﬁcantly elevated levels of D-
dimer in both the AAA and control group. Unfortunately,
we were unable to contact the authors to ascertain possible
reasons for these differences; closer analysis of the studies
does not explain the differences observed. Excluding these
studies from the meta-analysis does not change the overall
effect (MD, 290.76 ng/mL; 95% CI, 183.01-398.51 ng/
mL; P # .00001). Sensitivity analysis was performed
(Supplementary Fig 3, online only), and the plasmaD-dimer
concentration remained signiﬁcantly elevated in patients
with AAAs.Tissue plasminogen activator. Four studies reported
concentrations of plasma tissue plasminogen activator
(tPA),25,27,28,37 the largest of which contained 240 pa-
tients,27 whereas the smallest contained 142 patients.37
Methods were similar between three of the studies in that
they compared USS-detected AAA with age-matched
control subjects; however, the Fowkes et al25 AAA group
had a higher number of smokers and patients with chronic
obstructive pulmonary disease. Three studies reported no
signiﬁcant difference between plasma concentrations of
tPA in patients with and those without AAAs, whereas one
study found that patients with AAAs have a signiﬁcantly
higher concentration of tPA (Supplementary Table I, c,
online only). Pooled analysis of the data (Fig 5) reveals that
Fig 5. Forest plot compares mean plasma concentration of tissue plasminogen activator (tPA) between studies. A ﬁxed-
effects model was used for meta-analysis. AAA, Abdominal aortic aneurysm; CI, conﬁdence interval; SD, standard
deviation.
Fig 6. Forest plot compares mean plasma concentration of thrombin-antithrombin III complex (TAT) between
studies. A random-effects model was used for meta-analysis. AAA, Abdominal aortic aneurysm; CI, conﬁdence interval;
SD, standard deviation.
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plasma concentration of tPA to patients without (MD,
0.35 ng/mL; 95% CI, 0.23 to 0.93 ng/mL; P ¼ .24).
There was no signiﬁcant heterogeneity between studies
(I2 ¼ 43%), and accordingly, a ﬁxed-effect model was used.
Sensitivity analysis was not possible because of study sizes.
Plasminogen activator inhibitor type 1. Two studies
analyzed the concentration of plasminogen activator inhib-
itor type 1 (PAI-1)19,28 in patients with and those without
AAAs; neither found a signiﬁcant difference between the
two groups. One study analyzed PAI-1 activity,32 again
ﬁnding no signiﬁcant difference between patients with
AAAs and age-matched control subjects (Supplementary
Table I, d, online only).
Plasmin-antiplasmin complexes. One study38 re-
ported that plasmin-antiplasmin complex is signiﬁcantly,
positively correlated with AAA progression (r ¼ 0.39;
95% CI, 0.16-0.56; P < .001), a ﬁnding that persisted even
after adjustment for initial AAA size and smoking. Inter-
estingly, they also found that plasmin-antiplasmin complex
levels were signiﬁcantly predictive for which cases would
reach 55 mm within 5 years.
Markers of thrombin generation. Thrombin-
antithrombin III complex. Eight studies reported concen-
trations of thrombin-antithrombin III complex
(TAT),18,19,24,28,29,32,34,35 the largest of which contained
165 patients,28 whereas the smallest contained 43patients.29 Two studies found no signiﬁcant difference in
patients with and those without AAAs, whereas six studies
found a signiﬁcantly higher TAT concentration in patients
with AAAs (Supplementary Table I, e, online only). Pooled
analysis of the data (Fig 6) reveals that patients with AAAs
have a signiﬁcantly higher plasma concentration of TAT
(MD, 5.58 g/L; 95% CI, 3.34-7.83 g/L; P # .0001).
There was signiﬁcant heterogeneity between studies (I2 ¼
80%), and accordingly, a random-effects model was used.
Sensitivity analysis was performed (Supplementary Fig 4,
online only) and did not signiﬁcantly change the overall
effect.
Three studies reported on the association of AAA size
with plasma concentration of TAT,18,19,24 each ﬁnding a
positive association with the largest correlation coefﬁcient
value equaling 0.714.24 However, meta-regression of
studies18,19,28,29,32 reporting AAA diameter and TAT con-
centration revealed no signiﬁcant association (P ¼ .5).
Prothrombin fragments F1DF2. Three studies
analyzed the concentration of prothrombin fragments
F1þF2 (F1þ2)19,28,29 from which two studies found a
signiﬁcant elevation in patients with AAA, whereas one
found no difference (Supplementary Table I, f, online
only). Pooled analysis of the data (Fig 7) reveals that pa-
tients with AAAs do not have a signiﬁcantly different
plasma concentration of F1þ2 (MD, 0.11 ng/mL; 95%
CI, 0.39 to 0.61 ng/mL; P ¼ .66). There was signiﬁcant
Fig 7. Forest plot compares mean plasma concentration of prothrombin fragments F1þF2 between studies. A
random-effects model was used for meta-analysis. AAA, Abdominal aortic aneurysm; CI, conﬁdence interval; SD,
standard deviation.
Fig 8. Forest plot compares mean plasma concentration of platelet count between studies. A random-effects model was
used for meta-analysis. AAA, Abdominal aortic aneurysm; CI, conﬁdence interval; SD, standard deviation.
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ingly, a random-effects model was used. Sensitivity analysis
was not possible because of study sizes.
Platelet count. Six studies reported differences in
platelet count,16,18,19,31,39 the largest of which contained
3424 patients,31 whereas the smallest had 61 patients.18
Individually, two of the studies found a signiﬁcantly
lower platelet count in patients with AAAs, whereas four
did not ﬁnd any difference (Supplementary Table I, g,
online only). Pooled analysis of the data (Fig 8) reveals that
patients with AAAs and control subjects do not have a
signiﬁcantly different platelet count (MD, e11.21  109;
95% CI, 22.87  109 to 1.54  109; P ¼ .06). There
was signiﬁcant heterogeneity between studies (I2 ¼ 75%),
and accordingly, a random-effects model was used. Sensi-
tivity analysis was performed (Supplementary Fig 5, online
only) and did not signiﬁcantly change the overall effect.
DISCUSSION
This systematic review and meta-analysis comparing
hemostatic markers in patients with and those without
AAAs represents the largest of its kind to date and reveals
that there is a signiﬁcant association between the presence
of AAAs and plasma levels of ﬁbrinogen, D-dimer, and
TAT suggesting that AAAs are associated with increased
ﬁbrin turnover, ﬁbrinolysis, and thrombin generation.
Apart from its possible usefulness as a marker of aneurysm
presence, a signiﬁcant linear association exists between
D-dimer concentration and aneurysm diameter, whichsuggests that it may also be useful as a predictor of aneu-
rysm size.
The ﬁndings of this study are in keeping with a previ-
ous meta-analysis by Takagi et al,11 who demonstrated a
signiﬁcantly higher ﬁbrinogen and D-dimer concentration
in patients with AAAs compared with a control group.
By the inclusion of the most recent studies analyzing ﬁbrin-
ogen and D-dimer, we have been able to reﬁne the results
previously published to MD 0.43 g/L (95% CI, 0.28 g/L-
0.58 g/L; P # .00001) and MD 325.82 ng/mL (95% CI,
199.74 ng/mL-451.89 ng/mL; P# .00001), respectively.
Several studies have reported elevated levels of hemostatic
markers in patients with atherosclerosis; therefore, by
excluding patients with peripheral vascular disease from
the control groups, which has not been done previously,
these results should better reﬂect true differences between
patients with AAAs and normal healthy individuals.
The ﬁnding of an association between plasma ﬁbrin-
ogen, D-dimer and TAT concentration, and the presence
of AAAs is important because it reﬂects the pathophysi-
ology of AAAs. The coagulation cascade involves a com-
plex series of enzymatic reactions that culminate in
thrombin generation and the deposition of insoluble ﬁbrin.
TAT is an established marker of thrombin activation,
whereas the action of plasmin on cross-linked ﬁbrin gener-
ates degradation products including D-dimer.28 Although
it is possible that markers of hemostasis are involved in
the development of AAAs, as D-dimer has itself been
shown to stimulate the release of proinﬂammatory
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coagulation are known to fall after aortic aneurysm
repair,33 which suggests that the aneurysm itself drives
the changes observed in this study, reﬂecting the size and
continual remodelling of the intraluminal thrombus.18
This progressive coagulopathy appears to be proportional
to aortic diameter, and, given that a link between markers
of hemostasis and atherothrombosis is both likely and plau-
sible, this highlights the importance of addressing all modi-
ﬁable cardiovascular risk factors in patients with AAAs.
Although it is unlikely that these biomarkers will
replace ultrasound as a ﬁrst-line diagnostic tool for the
presence of AAAs, one possible strategy to reduce the
cost of negative screening is to use a two-stage approach
with the use of a cheaper high-sensitivity diagnostic test
such as D-dimer, followed up with a high-speciﬁcity test
such as ultrasound. Recent evidence that the current prev-
alence of AAAs in the NHS AAA Screening Programme
target population of 65-year-old men is 1.5% (NAAASP
2011-2012), lower than the 4.7% prevalence observed in
MASS,41 may make this a realistic future prospect; howev-
er, these results must be interpreted with caution because
D-dimer, like most biomarkers of AAAs, is not disease-
speciﬁc.
Elevated levels of hemostatic markers have been re-
ported in patients with atherosclerosis and in smokers and
as an acute-phase response, for example, in patients with in-
fections; however, the majority of studies in this review did
not control for these variables. Golledge et al23 showed
that D-dimer levels are higher in patients with AAAs as
compared with those with peripheral artery disease alone.
Five studies23,28,31,37,42 had a signiﬁcantly higher number
of smokers in their AAA group; however, Lee et al27 showed
that after adjustments for pack-years, an SD increase
(0.76 g L1) in ﬁbrinogen was associated with a signiﬁcant
increase in the risk of AAAs. One study18 excluded patients
with a C-reactive protein level >0.4 mg/dL in an attempt
to exclude patients whose markers may be raised as an
acute-phase response and found signiﬁcantly elevated levels
of TAT and D-dimer with a signiﬁcantly lower platelet
count.
One limitation of this study is that some of the
included studies have small patient numbers, and the num-
ber of patients in the meta-analysis of TAT is signiﬁcantly
smaller than that for ﬁbrinogen or D-dimer; however, in-
clusive of all studies, we were able to analyze 9862 patients.
Another limitation is that it does not take into account that
some patients with AAAs have little or no mural thrombus,
and most of the studies included did not quantify levels of
thrombus on the basis of radiographic data. Yamazumi
et al18 demonstrated that maximum thickness of mural
thrombus is signiﬁcantly, positively correlated with preop-
erative levels of TAT and D-dimer, and another study20
found that ﬁbrinogen levels were positively correlated
with the percentage of intraluminal thrombus occupying
the lumen (r ¼ 0.36; P < .05). Shindo et al,22 however,
revealed that although thrombus volume was strongly
correlated with the volume and diameter of the AAA(r ¼ 0.6; P # .01), it was not associated with coagulation
factors. Taken together, these ﬁndings suggest that these
markers may not be useful in patients with little or no
intraluminal thrombus. Future studies of the use of hemo-
static markers in identifying patients with AAAs should
match patients for both age and smoking habits and should
exclude patients with peripheral vascular disease. Further
analysis of the use of hemostatic markers to predict aneu-
rysm presence and size is necessary to determine any poten-
tial role in new diagnostic/prognostic pathways for patients
with AAAs.
CONCLUSIONS
This study reveals that there is a signiﬁcant association
between the presence of AAAs and plasma levels of ﬁbrin-
ogen, D-dimer, and TAT, which suggests that AAAs are
associated with increased ﬁbrin turnover, ﬁbrinolysis, and
thrombin generation. The importance of this ﬁnding is to
focus the clinician’s attention to address modiﬁable cardio-
vascular risk factors when possible. D-dimer may have a
role as a future biomarker of AAA; however, further
research is needed.
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Supplementary Fig 1 (online only). a, Funnel plot of studies included for meta-analysis of ﬁbrinogen. b, Funnel plot
of studies included for meta-analysis of D-dimer. c, Funnel plot of studies included for meta-analysis of tissue plas-
minogen activator. d, Funnel plot of studies included for meta-analysis of thrombin-antithrombin III complex (TAT).
e, Funnel plot of studies included for meta-analysis of prothrombin fragments F1þF2. f, Funnel plot of studies included
for meta-analysis of platelet count.
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Supplementary Fig 2 (online only). Sensitivity analysis: Fibrinogen. AAA, Abdominal aortic aneurysm; CI, conﬁ-
dence interval; SD, standard deviation.
Supplementary Fig 3 (online only). Sensitivity analysis: D-dimer. AAA, Abdominal aortic aneurysm; CI, conﬁdence
interval; SD, standard deviation.
Supplementary Fig 4 (online only). Sensitivity analysis: Thrombin-antithrombin III complex (TAT). AAA,
Abdominal aortic aneurysm; CI, conﬁdence interval; SD, standard deviation.
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Supplementary Fig 5 (online only). Sensitivity analysis: Platelet count. AAA, Abdominal aortic aneurysm; CI,
conﬁdence interval; SD, standard deviation.
Supplementary Table I (online only). a, Studies
comparing ﬁbrinogen concentration in patients with and
those without abdominal aortic aneurysms (AAAs)
Author Year Increased in P value
Al-Barjas20 2006 AAA >.01
Blann17 1998 NS .185
Fowkes25 2006 AAA .02
Jelenska26 2004 AAA <.001
Lee27 1996 AAA <.001
Parry28 2009 AAA .19
Yamazumi18 1998 NS .21
Spring16 2006 AAA <.0001
Holmberg33 1999 AAA <.001
Singh (men)31 2001 AAA <.001
Singh (women)31 2001 AAA <.001
Franks30 1996 NS .57
NS, Not speciﬁed.
Supplementary Table I (online only). b, Studies
comparing D-dimer concentration in patients with and
those without abdominal aortic aneurysms (AAAs)
Author Year Increased in P value
Fowkes25 2006 AAA <.001
Ihara34 2003 AAA <.0001
Nomura24 2003 AAA .0001
Jelenska26 2004 AAA <.001
Lee27 1996 AAA <.001
Parry28 2009 AAA <.001
Yamazumi18 1998 AAA <.01
Wallinder19 2009 AAA .001
Golledge23 2009 AAA <.001
Serino36 2002 AAA <.05
Aramoto35 1994 NS NS
NS, Not speciﬁed.
Supplementary Table I (online only). c, Studies
comparing tissue plasminogen activator concentration in
patients with and those without abdominal aortic
aneurysms (AAAs)
Author Year Increased in P value
Fowkes25 2006 NS .64
Parry28 2009 NS .719
Wanhainen19 2007 AAA .016
Abdelhamid32 2013 NS NS
NS, Not speciﬁed.
Supplementary Table I (online only). d, Studies
comparing plasminogen activator inhibitor concentration
in patients with and those without abdominal aortic
aneurysms (AAAs)
Author Year Increased in P value
Parry28 2009 NS .619
Wallinder19 2009 NS NS
Abdelhamid32 2013 NS NS
NS, Not speciﬁed.
Supplementary Table I (online only). e, Studies
comparing thrombin-antithrombin III complex (TAT)
concentration in patients with and those without
abdominal aortic aneurysms (AAAs)
Author Year Increased in P value
Ihara34 2003 AAA <.0001
Nomura24 2003 AAA .0001
Parry28 2009 AAA <.001
Yamazumi18 1998 AAA <.01
Wallinder19 2009 AAA <.001
Abdelhamid32 2013 NS NS
Aramoto35 1994 AAA NS
Holmberg33 1999 AAA .001
NS, Not speciﬁed.
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Supplementary Table I (online only). f, Studies
comparing prothrombin fragments F1þF2 concentration
in patients with and those without abdominal aortic
aneurysms (AAAs)
Author Year Increased in P value
Parry28 2009 AAA .019
Wallinder19 2009 NS NS
Holmberg33 1999 AAA .001
NS, Not speciﬁed.
Supplementary Table I (online only). g, Studies
comparing platelet count in patients with and those
without abdominal aortic aneurysms (AAAs)
Author Year Increased in P value
Milne39 1999 Control <.0001
Yamazumi18 1998 Control .05
Spring16 2006 NS .5486
Wallinder19 2009 NS NS
Singh (men)31 2001 NS .08
Singh (women)31 2001 NS .9
NS, Not speciﬁed.
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